Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Goserelin
Drug ID BADD_D01038
Description Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Indications and Usage Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
Marketing Status Prescription
ATC Code L02AE03
DrugBank ID DB00014
KEGG ID D04405
MeSH ID D017273
PubChem ID 5311128
TTD Drug ID D00BCG
NDC Product Code 70720-951; 55463-0005; 70720-950
Synonyms Goserelin | ICI-118630 | ICI 118630 | ICI118630 | Zoladex | Goserelin Acetate | Acetate, Goserelin
Chemical Information
Molecular Formula C59H84N18O14
CAS Registry Number 65807-02-5
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C( CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C 6CCC(=O)N6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.0030.002942%
Paraesthesia17.02.06.005--
Paranoia19.05.01.0050.001471%Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Peripheral vascular disorder24.03.01.003--Not Available
Pharyngitis11.01.13.003; 07.05.07.004; 22.07.03.004--
Photosensitivity reaction23.03.09.003--
Pituitary infarction24.04.06.016; 18.02.02.004; 17.08.01.027; 05.03.04.006--Not Available
Pituitary tumour16.24.01.003; 05.03.05.002--Not Available
Plasma cell myeloma16.23.02.004; 01.14.02.004--Not Available
Platelet count decreased13.01.04.001--
Pleural effusion22.05.02.0020.001471%
Pneumonia11.01.09.003; 22.07.01.0030.005148%Not Available
Pollakiuria20.02.02.007--
Proctitis07.08.04.001--
Prostate cancer metastatic21.04.02.004; 16.25.01.0020.001151%Not Available
Prostatic specific antigen increased13.22.01.0010.003677%Not Available
Pruritus23.03.12.0010.004413%
Pulmonary embolism24.01.06.001; 22.06.02.0010.005148%Not Available
Pyrexia08.05.02.0030.005148%
Rash23.03.13.001--Not Available
Rectal haemorrhage07.12.03.001; 24.07.02.0180.002942%
Renal failure20.01.03.005--Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.001471%
Rhinitis22.07.03.006; 11.01.13.004--
Scratch12.01.06.009; 23.03.11.0170.001471%Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 11 Pages